Prevention and Management of Acute Radiation Dermatitis

Topical non-steroidal agents
• Consensus to recommend (≥75%): no recommendation.
• Near-consensus supporting recommendation (60–74%): no recommendation.

Topical corticosteroids
• Consensus to recommend (≥75%): mometasone and betamethasone.
• Near-consensus supporting recommendation (60–74%): no recommendation.

Barrier films and dressings
• Consensus to recommend (≥75%): silicone-based polyurethane (Mepitel film) for breast cancer and polyurethane film (Hydrofilm).
• Near-consensus supporting recommendation (60–74%): silicone-based polyurethane (Mepitel film) for head and neck cancer and silver nylon dressing.

Laser therapy
• Consensus to recommend (≥75%): photobiomodulation or low-level laser therapy for breast cancer.
• Near-consensus supporting recommendation (60–74%): no recommendation.

Natural and miscellaneous agents
• Consensus to recommend (≥75%): olive oil.
• Near-consensus supporting recommendation (60–74%): curcumin (turmeric)-based products and silymarin-based products.

Growth factors and oral agents
• Consensus to recommend (≥75%): no recommendation.
• Near-consensus supporting recommendation (60–74%): enzyme mixture (papain, trypsin, and chymotrypsin).

Antibiotics
• Consensus to recommend (≥75%): no recommendation.
• Near-consensus supporting recommendation (60–74%): sulfadiazine silver.

Antiperspirant or deodorant
• Consensus to recommend (≥75%): no recommendation.
• Near-consensus supporting recommendation (60–74%): no recommendation.

Alternative and multicomponent therapies
• Consensus to recommend (≥75%): no recommendation.
• Near-consensus supporting recommendation (60–74%): lotion (3% urea, polidocanol, and hyaluronic acid).